SCREENING FOR HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/c61hsw19Keywords:
Screening, early detection, hepatocellular carsinoma, chronic liver diseaseAbstract
Background: Chronic liver disease is the most significant risk factors for the development of hepatocellular carcinoma (HCC). High-risk patients should undergo routine screening for HCC, but it is unclear how much data there is to support this suggestion.
The aim: This study aims to determine the screening options for hepatocellular carcinoma in chronic liver disease.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and ScienceDirect, were used to do this. It was decided not to take into account review pieces, identical works that had already been published, or works that were only half done.
Results: In the PubMed database, the results of our search brought up 110 articles, whereas the results of our search on ScienceDirect brought up 285 articles. The results of the search conducted by title screening yielded a total 29 articles for PubMed and 15 articles for ScienceDirect. We compiled a total of 6 papers, 2 of which came from PubMed and 4 of which came from ScienceDirect. We excluded 1 review article. In the end, we included five research that met the criteria.
Conclusion: Multitarget HCC panel; combined methylation (CDH1, DNMT3b or ESR1); CARD10; COP; combination of CRD9, CARD10, and COP; and PKCwere accurate for HCC screening (any stage of severity) in CLD with pooled sensitivities more than 80%. However, there is not adequate data to make definite judgements about the balance between the advantages and disadvantages of routine screening for HCC.
References
Sharma A, Nagalli S. Chronic Liver Disease [Internet] 2023. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK554597/#:~:text=Chronic
Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma [Internet] 2016 Oct;Volume 3:41–53. Available from: https://www.dovepress.com/hepatocellular-carcinoma-a-review-peer-reviewed-article-JHC
Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Vol. 17, Clinical Liver Disease. John Wiley and Sons Inc; 2021. p. 365–70.
Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH, et al. Association between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Journal of Infectious Diseases. 2021 Jul 15;224(2):294–302.
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Vol. 73, Hepatology. John Wiley and Sons Inc; 2021. p. 4–13.
Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: A systematic review. Vol. 161, Annals of Internal Medicine. American College of Physicians; 2014. p. 261–9.
Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, et al. A Novel BloodBased Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. 2021 Dec 1;19(12):2597-2605.e4.
Chen Y, Yang X, Shao Y, Zhao H, Jiang J, Huang P, et al. Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study. Ann Hepatol. 2023 Jul 1;28(4).
Dou CY, Fan YC, Cao CJ, Yang Y, Wang K. Sera DNA Methylation of CDH1, DNMT3b and ESR1 Promoters as Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2016 Apr 1;61(4):1130–8.
Oikawa T, Yamada K, Tsubota A, Saeki C, Tago N, Nakagawa C, et al. Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma. Gastro Hep Advances. 2023;2(1):83–95.
Zekri AR, El-Kassas M, Saad Y, Bahnassy A, Khatab Sameh Seif El-Din H, Darweesh SK, et al. Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients. Vol. 12. 2013.
Hasani A. Factors affecting screening for hepatocellular carcinoma. Ann Hepatol. 2014;13(2):204–10.
Carter HE, Jeffrey GP, Ramm GA, Gordon LG. Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma. Value in Health. 2021 Oct 1;24(10):1454–62.
Fitzmorris P, Singal AK. Surveillance and Diagnosis of Hepatocellular Carcinoma. Vol. 11, Gastroenterology & Hepatology. 2015.
Parikh ND, Tayob N, Al-Jarrah T, Kramer J, Melcher J, Smith D, et al. Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. JAMA Netw Open. 2022 Jul 22;5(7):E2223504.
Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022 Jul 1;77(1):128–39.
Yang J, Yang Z, Zeng X, Yu S, Gao L, Jiang Y, et al. Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: Systematic review and meta-analysis. Journal of the National Cancer Center. 2023 Sep 1.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
